Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout - Pharmaceutical Technology

If approved, Perfuse's PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea. If approved, the deal’s centrepiece, PER-001, could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea. The centrepiece of Bayer’s Perfusa acquisition is PER-001 an endothelin receptor antagonist. Credit: Edgar Martirosyan / Shutterstock.com. Bayer is handing over up to $2.45bn to acquire Perfuse Therapeutics – marking the company’s first bid to enhance its legacy in the ophthalmology market since the patent expiry of its best-selling eye drug, Eylea (aflibercept). Through this deal, Bayer will pay $300m upfront and up to $2.15bn in…

Source: Pharmaceutical Technology